Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of May 2025, specifically dated May 7, 2025. Haleon Plc is a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company operates under the ticker symbols HLN on the LSE and NYSE.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. This document serves as a notification of a corporate action rather than a financial results report.
Material Changes
The primary material event disclosed is the publication of updated listing particulars for Haleon's Euro Medium Term Note ("EMTN") Programme. This update is described as a routine annual update.
- Programme Size: £10,000,000,000 (10 billion GBP).
- Issuers: Haleon UK Capital plc and Haleon Netherlands Capital B.V.
- Guarantor: Haleon Plc.
- Date of Publication: May 7, 2025.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of specific risks or contingencies related to business performance. A standard disclaimer notes that the information in the Listing Particulars is targeted at residents of specific countries and should not be relied upon by persons outside those jurisdictions without verification.
Key Facts for Investor Verification
- Verify the full text of the "Listing Particulars" dated May 7, 2025, available at www.haleon.com/investors/debt-investors.
- Confirm the specific terms and conditions of the £10 billion EMTN Programme.
- Check the geographic restrictions on the offer contained in the Listing Particulars to ensure compliance with local regulations.
- Note that this filing does not contain updated financial performance data; refer to the most recent Form 20-F or quarterly reports for financial metrics.